^
Association details:
| Biomarker: | FGFR1 amplification + HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | lucitanib (E 3810) (FGFR inhibitor, VEGFR inhibitor, Tyrosine kinase inhibitor, PDGFR α-β inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Lucitanib for the Treatment of HR +/HER2 - Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
Excerpt:
The FGFR1 gene is amplified in 14% of patients with HR + /HER2 - breast cancer...Patients with higher FGFR1 expression (H-score ≥ 50) also had nominally longer median PFS than those with FGFR-low tumors (H-score < 50) by 103 days [approximately 3 months; 212 (165–NA) days vs. 109 (57–158) days.
DOI:
10.1158/1078-0432.CCR-19-1164
